Listen
VAXIGRIP (trivalent influenza vaccine (split virion, inactivated)) - Influenza vaccine
Reason for request
Summary of opinion
Favourable opinion for reimbursement in the prevention of influenza in adults and childrefrom 6 months of age and in accordance with the current vaccination recommendations (HAS opinion of 6 February 2025).
Clinical Benefit
| Substantial |
The Committee considers that the clinical benefit of VAXIGRIP (trivalent influenza vaccine (split virion, inactivated)) is substantial in the prevention of influenza in adults and children from 6 months of age in accordance with the current HAS vaccination recommendations dating from 6 February 2025. |
Clinical Added Value
| no clinical added value |
The change from tetravalent to trivalent is not of a nature to modify the clinical added value. The Committee considers that VAXIGRIP (trivalent influenza vaccine (split virion, inactivated)) provides no clinical added value (CAV V), in adults and children from 6 months of age for whom vaccination is recommended, compared to the other vaccines recommended in the prevention of seasonal influenza. |
